Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Gillard, Paul ^a   Chu, Daniel Wai Sing ^b   Hwang, Shinn Jang ^c   Yang, Pan Chyr ^d   Thongcharoen, Prasert ^e   Lim, Fong S ^f   Dramé, Mamadou ^g   Walravens, Karl ^a   Roman, François ^a  

^a GSK   (Belgium)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e MAHIDOL UNIVERSITY   (Thailand)

^f NATIONAL HEALTHCARE GROUP POLYCLINICS   (Singapore)

^g GLAXOSMITHKLINE   (United States)

Author keywords

AS03A adjuvant; H5N1; Pandemic influenza; Prime boost

Indexed keywords

CD4 ANTIBODY; CD40 LIGAND; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; NEUTRALIZING ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; APPENDICITIS; ARTICLE; ASIAN; AVIAN INFLUENZA; BENIGN TUMOR; BRAIN DISEASE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLAVICLE FRACTURE; COLON POLYP; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE FRACTURE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HELICOBACTER INFECTION; HEMAGGLUTINATION INHIBITION TEST; HONG KONG; HUMAN; HUMORAL IMMUNITY; ILEUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; JOINT DISLOCATION; LIGAMENT RUPTURE; LUNG EMBOLISM; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; OVARY TUMOR; PANDEMIC INFLUENZA; PHASE 3 CLINICAL TRIAL; PYELONEPHRITIS; RHINOPHARYNGITIS; SINGAPORE; TAIWAN; THAILAND; TONSILLITIS; TOOTH DISEASE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; CROSS REACTION; EVALUATION STUDY; INFLUENZA VACCINATION; INJECTION SITE REACTION; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALPHA-TOCOPHEROL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS REACTIONS; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; YOUNG ADULT;

EID: 84899098483     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-142     Document Type: Article

References (26)

1. World Health Organization Cumulative Number Of Confirmed Human Cases For Avian Influenza A(H5n1) Reported To Who, 2003-2013. 2013, http://www.who.int/influenza/human_animal_interface/EN_GIP_20130705CumulativeNumberH5N1cases_2.pdf, World Health Organization.
2. Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu Y, Li X, Yan J, Liu W, Zhao G, Yang W, Wang Y, Ma J, Shu Y, Lei F, Gao GF. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 1926-1932, 2013:381.
3. World Health Organization Antigenic And Genetic Characteristics Of Zoonotic Influenza Viruses And Development Of Candidate Vaccine Viruses For Pandemic Preparedness. 2013, http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf, World Health Organization.
4. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589. 10.1016/S0140-6736(07)61297-5, 17707753.
5. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3:e1665. 10.1371/journal.pone.0001665, 2253495, 18301743.
6. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452. 10.1038/nature04795, 16642006.
7. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8:650-658. 10.1016/S1473-3099(08)70232-9, 18922487.
8. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653. 10.1086/652701, 20423222.
9. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011, 203:1729-1738. 10.1093/infdis/jir172, 3100510, 21606531.
10. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9:1057-1071. 10.1517/14712590903066695, 19555313.
11. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Drame M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290. 10.1016/j.vaccine.2009.01.040, 19856521.
12. Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Drame M, Schwarz TF. An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respi Viruses 2013, 7:55-65.
13. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Drame M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou R. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435. 10.1016/j.vaccine.2009.07.102, 19683087.
14. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103:163-171. 10.1016/j.virusres.2004.02.029, 15163505.
15. Kendal A, Pereira M, Skehel J. Hemagglutination Inhibition. Concepts And Procedures For Laboratory-Based Influenza Surveillance 1982, B17-35. Atlanta: Centers for Disease Control and Prevention and Pan-American Health Organization, Kendal AP, Pereira MS, Skehel JJ.
16. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943. 88628, 10074505.
17. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103:91-95. 10.1016/j.virusres.2004.02.019, 15163495.
18. Reed L, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
19. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M, Planelles M, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P. Immunogenicity and safety of H5N1 a/Vietnam/1194/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infec Dis J 2010, 29:e35-e46.
20. Maecker H, Maino V, Picker L. Immunofluorescence analysis of T-Cell responses in health and disease. J Clin Immun 2000, 20:391-399. 10.1023/A:1026403724413, 11202228.
21. Waldrop S, Davis K, Maino V, Picker L. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 1998, 161:5284-5295.
22. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, Abernathy RA, Clarke M, Conn L, Kwong H, Lee M, Au G, Ho YY, Mak KH, Cox NJ, Fukuda K. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999, 180:1763-1770. 10.1086/315137, 10558929.
23. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Drame M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G. Priming with AS03(A)-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857. 10.1016/j.vaccine.2009.10.017, 19835828.
24. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-adjuvanted influenza a (H1N1) 2009 vaccine for adults up to 85 years of Age. Clin Infect Dis 2009, 2010(51):668-677.
25. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, Huston G, Jones SC, Kamperschroer C, Lee WH, McKinstry KK, Roman E, Strutt T, Weng. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 2006, 211:8-22. 10.1111/j.0105-2896.2006.00388.x, 2266984, 16824113.
26. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454. 10.1007/s10875-010-9490-6, 3132412, 21174144.